Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Legal Officer | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,110 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12 | Direct | 111,251 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Jan 31, 2026 01:38 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-26-000004 · wk-form4_1769823507.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Jan 31, 2026 01:38 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-26-000004 · wk-form4_1769823507.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Jan 31, 2026 01:38 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-26-000004 · wk-form4_1769823507.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Jan 31, 2026 01:38 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-26-000004 · wk-form4_1769823507.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 00:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001817199-26-000002 · wk-form4_1768957074.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,643 Underlying: Common Stock · 3,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 00:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,760 | $18.42 | $69,273.11 |
DisclosureSEC source: 0001817199-26-000002 · wk-form4_1768957074.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,897 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.18 and the highest price at which shares were sold was $18.69. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 00:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,760 | $1.86 | $6,993.60 |
DisclosureSEC source: 0001817199-26-000002 · wk-form4_1768957074.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001817199-25-000010 · wk-form4_1766099295.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,403 Underlying: Common Stock · 3,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 200 | $18.56 | $3,711.00 |
DisclosureSEC source: 0001817199-25-000010 · wk-form4_1766099295.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,897 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.55 and the highest price at which shares were sold was $18.56. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,560 | $17.87 | $63,603.32 |
DisclosureSEC source: 0001817199-25-000010 · wk-form4_1766099295.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,097 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.53 and the highest price at which shares were sold was $18.18. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 23:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,760 | $1.86 | $6,993.60 |
DisclosureSEC source: 0001817199-25-000010 · wk-form4_1766099295.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 24, 2025 Filed Nov 24, 2025 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 37,600 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001817199-25-000007 · wk-form4_1764025585.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,163 Underlying: Common Stock · 37,600 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| November 24, 2025 Filed Nov 24, 2025 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 37,600 | $17.07 | $641,696.64 |
DisclosureSEC source: 0001817199-25-000007 · wk-form4_1764025585.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,897 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 24, 2025 Filed Nov 24, 2025 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 37,600 | $1.86 | $69,936.00 |
DisclosureSEC source: 0001817199-25-000007 · wk-form4_1764025585.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · derivative · entry 9 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,584 Underlying: Common Stock · 2,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · derivative · entry 8 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · derivative · entry 7 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,925 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,644 | $12.80 | $46,631.17 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · nonDerivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,897 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.68 and the highest price at which shares were sold was $12.89. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 22:02 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001817199-25-000005 · wk-form4_1761861746.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · derivative · entry 9 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,442 Underlying: Common Stock · 2,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · derivative · entry 8 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · derivative · entry 7 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,849 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,841 | $12.01 | $46,134.25 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · nonDerivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,009 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.78 and the highest price at which shares were sold was $12.315. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 22:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000100 · wk-form4_1753915738.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · derivative · entry 7 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,773 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,894 | $11.50 | $33,285.92 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,318 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.05 and the highest price at which shares were sold was $11.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed Apr 30, 2025 23:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000060 · wk-form4_1746056122.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:12 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 34,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000033 · wk-form4_1739481123.xml · derivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,300 Underlying: Common Stock · 34,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:12 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.12 | $0.00 |
DisclosureSEC source: 0001549595-25-000033 · wk-form4_1739481123.xml · derivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-02-10 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 11, 2025, until the option is fully vested on February 10, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,537 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-25-000026 · wk-form4_1738631019.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,537 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 223 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-25-000026 · wk-form4_1738631019.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,763 Underlying: Common Stock · 223 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 100 | $20.48 | $2,048.00 |
DisclosureSEC source: 0001549595-25-000026 · wk-form4_1738631019.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,538 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,660 | $19.94 | $112,885.87 |
DisclosureSEC source: 0001549595-25-000026 · wk-form4_1738631019.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,638 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $19.465 and the highest price at which shares were sold was $20.42. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,537 | $1.86 | $10,298.82 |
DisclosureSEC source: 0001549595-25-000026 · wk-form4_1738631019.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:03 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 223 | $1.86 | $414.78 |
DisclosureSEC source: 0001549595-25-000026 · wk-form4_1738631019.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · derivative · entry 8 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · derivative · entry 7 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,697 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.